Psilocybin mushrooms (“shrooms” or “magic mushrooms”) are fungi that produce a naturally occurring psychedelic compound called psilocybin. When ingested, your body converts psilocybin into its active form, psilocin, which binds to serotonin receptors in the brain and produces altered perception, emotional shifts, and hallucinations that typically last 3 to 6 hours. Whether you’re curious about therapeutic research, safety, or legal status, here’s what the science actually says.
How Psilocybin Works in the Brain
When you eat psilocybin mushrooms, your liver converts psilocybin into psilocin. Psilocin is the molecule that actually crosses into the brain and produces psychedelic effects. It works primarily by binding to a specific type of serotonin receptor called 5-HT2A, which is concentrated in the outer layers of the brain responsible for perception, mood, and cognition. PET imaging studies have shown that a single dose can occupy 43 to 72% of these receptors, depending on the amount taken, with a maximum occupancy ceiling around 77%.
Psilocin also has weaker activity at a few other serotonin receptor subtypes, but its attraction to the serotonin transporter (the protein that recycles serotonin between neurons) is roughly 100 times lower than its affinity for 5-HT2A. This is important because it means psilocybin works through a fundamentally different mechanism than SSRI antidepressants, which primarily target that transporter.
What the Experience Feels Like and How Long It Lasts
Effects typically begin within 20 to 40 minutes of ingestion, though eating them on a full stomach can delay the onset. The experience generally lasts 3 to 6 hours total, with the most intense period (often called the “peak”) falling roughly in the middle. Common effects include visual distortions like intensified colors, geometric patterns, and trails behind moving objects. Emotional responses can range from profound feelings of connection and awe to anxiety and confusion, sometimes within the same session.
Physical effects are relatively mild for most people: dilated pupils, slight nausea (especially in the first 30 minutes), changes in heart rate, and yawning. The nausea tends to pass as the psychological effects take hold.
Dosage Ranges
Doses are measured in dried grams of mushroom, most commonly Psilocybe cubensis, which contains roughly 1% psilocybin by weight. The general ranges researchers and experienced users reference are:
- Standard dose: about 2.5 grams of dried mushrooms
- High dose: about 3.5 grams
- Very high dose: 5 to 6 grams
These numbers assume Psilocybe cubensis specifically. Potency varies significantly between species and even between batches of the same species, which makes precise dosing difficult outside of a clinical setting where synthetic psilocybin is weighed to the milligram. Clinical trials most commonly use 25 mg of pure psilocybin, equivalent to roughly 2.5 grams of dried cubensis.
Therapeutic Research for Depression
Psilocybin has drawn serious clinical attention as a treatment for depression, particularly treatment-resistant depression where standard medications haven’t worked. Across 19 studies involving 423 participants with major depression, about 79% showed clinician-judged improvement after psychedelic-assisted therapy.
In one early trial, participants received psilocybin in two sessions. At one week after treatment, 71% were responders, and 67% still showed meaningful improvement at three months. A larger trial comparing different doses found that 37% of participants responded to the 25 mg dose at three weeks, compared to 18% in the control group. When psilocybin was tested head-to-head against a placebo, response rates were striking: 58% for psilocybin versus 16% for placebo on clinician-rated scales.
These results are promising but come with caveats. By 12 weeks in the larger trial, only 20% of the high-dose group had sustained their response. Psilocybin therapy also involves extensive psychological preparation and guided sessions, not just taking a pill. Phase 3 trials are underway, and regulatory approval remains a possibility in coming years, though not a certainty.
Interactions With Antidepressants
If you’re taking an SSRI or SNRI antidepressant, psilocybin’s effects will likely be weaker. In a survey of over 600 reports of people taking mushrooms while on antidepressants, about 47% of SSRI users and 55% of SNRI users reported weaker effects than expected. For comparison, only 29% of people on bupropion (which works through different brain chemistry) reported reduced effects.
What surprises many people is how long this dampening lasts after stopping the medication. In over 1,500 reports from people who had discontinued SSRIs or SNRIs, the probability of reduced effects didn’t return to normal until 3 to 6 months after the last dose. This does not mean you should stop your antidepressant to try mushrooms. Abruptly discontinuing antidepressants carries its own serious risks.
Safety and Physical Toxicity
Psilocybin has an extremely wide margin between an active dose and a physically dangerous one. No confirmed human deaths from psilocybin toxicity alone appear in the medical literature. The primary risks are psychological, not physical: intense anxiety or panic during the experience, dangerous behavior while disoriented, and rare but real lasting perceptual changes.
One recognized long-term risk is Hallucinogen Persisting Perception Disorder (HPPD), estimated to affect about 4.2% of people who use hallucinogens. Symptoms include visual disturbances like seeing halos around objects, trails behind moving things, flashes of color, or objects appearing larger or smaller than they are. The milder form (HPPD I) is brief and not particularly distressing. The more serious form (HPPD II) is long-lasting, sometimes irreversible, and can co-occur with anxiety, panic disorder, and depression. There’s no reliable way to predict who will develop it.
The Danger of Misidentification
One of the most concrete physical risks associated with psilocybin mushrooms has nothing to do with psilocybin itself. Most psilocybin-containing species are small, brown, and unremarkable in appearance. They look very similar to other small brown mushrooms, some of which are deadly. Since the 1960s, there have been numerous severe poisonings from people who consumed Galerina mushrooms (which contain the same toxins as death cap mushrooms) after mistaking them for Psilocybe species. Foraging for wild psilocybin mushrooms without expert-level mycology knowledge is genuinely dangerous.
Set and Setting
“Set” refers to your psychological mindset going into the experience. “Setting” refers to the physical, social, and cultural environment where it takes place. Both profoundly influence whether a psilocybin experience feels meaningful or terrifying. In clinical research, sessions are conducted in comfortable, dimly lit rooms designed to feel like a living room rather than a hospital. Participants recline on a couch, wear eyeshades, and listen to curated playlists of calming music to help direct attention inward. Two trained guides are present throughout to provide reassurance without directing the experience.
These protocols exist because anxiety during a psychedelic experience can escalate quickly. Feeling safe, being in a familiar or comfortable environment, and having a trusted, sober person present are the most effective tools for reducing the likelihood of a distressing experience.
Legal Status in the United States
Psilocybin remains a Schedule I controlled substance under federal law. However, the legal landscape at the state and local level has shifted considerably.
Oregon became the first state to legalize psilocybin-assisted therapy in 2020, with licensed service centers now operating. Colorado followed in 2022, legalizing and regulating psychedelics and treatment centers for their use. New Mexico signed the Medical Psilocybin Act into law in April 2025, establishing the third state-level access system, aiming to launch in late 2026. New Jersey has created a two-year psilocybin therapy pilot program at three hospitals. Washington state runs a psilocybin therapy pilot through the University of Washington specifically for veterans and first responders.
At the local level, several cities have made personal possession the lowest law enforcement priority, including Oakland, Santa Cruz, San Francisco, and Berkeley in California; Seattle, Port Townsend, and Olympia in Washington; and Ann Arbor, Detroit, and Hazel Park in Michigan. Nevada decriminalized possession of 4 ounces or less of psilocybin-producing fungi in 2023 for adults 18 and older. None of these local measures make psilocybin fully legal, but they effectively remove the threat of prosecution for personal use.